i-Cordis — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

i-Cordis is a private, preclinical biotech focused on revolutionizing the treatment of heart failure with preserved ejection fraction (HFpEF) through immunomodulation. The company's lead asset is a PEGylated derivative of pirfenidone, designed to overcome the original drug's limitations (e.g., frequent dosing, CNS side effects) while enhancing cardioprotective effects. With a strong scientific foundation based on the Phase II PIROUETTE trial data for pirfenidone in HFpEF and a world-class team of cardiac immunology experts, i-Cordis is positioning its novel compound as a potential first-in-class therapy for a large, underserved patient population.

Cardiovascular

Technology Platform

Medicinal chemistry platform for PEGylation of small molecule drugs to improve pharmacokinetics (extend half-life, reduce CNS penetration) while maintaining oral bioavailability.

Opportunities

The primary opportunity is addressing the massive, underserved HFpEF market, where only one drug class is approved.

Positive Phase II data for the parent drug, pirfenidone, provides strong clinical validation for the mechanism.

The PEGylation platform could create a best-in-class therapy with superior dosing and side-effect profile, enabling significant market penetration and potential expansion into secondary cardiac indications.

Risk Factors

High preclinical and clinical development risk: the novel PEGylated compound may not demonstrate expected improvements in efficacy or tolerability.

Competitive risk from established SGLT2 inhibitors and potential future generic pirfenidone.

Financial risk associated with raising sufficient capital to advance through clinical trials as a private, pre-revenue company.

Competitive Landscape

In HFpEF, i-Cordis would compete directly with SGLT2 inhibitors (e.g., empagliflozin, dapagliflozin), which are now standard of care. It also faces potential competition from other novel mechanisms in development and, longer-term, from generic pirfenidone if it pursues the HFpEF indication. Its differentiation strategy is based on improved pharmacokinetics and tolerability over the parent molecule.

More companies in Digital Health & Biotech SaaS →More companies in United States →